Document is current
Any future updates will be listed below
-
Authors
Palese, Alvisa https://orcid.org/0000-0002-3508-844X
Chiappinotto, Stefania
Fonda, Federico
Visintini, Erica
Peghin, Maddalena
Colizzi, Marco
Balestrieri, Matteo
De Martino, Maria
Isola, Miriam
Tascini, Carlo
- License Information
-
More Information
Article History
Received: 29 December 2022
Accepted: 23 September 2023
First Online: 31 October 2023
Declarations
:
: This is a methodological paper. Ethical approval of the longitudinal study CORonavirus MonitoRing Study (CORMOR) part 3 and part 4 was given by the Ethics Committee of the Region Friuli-Venezia Giulia, Italy (CEUR-2020-OS-219 and CEUR-2020-OS-205).
: Not applicable.
: MC has been a consultant/advisor to GW Pharma Limited, GW Pharma Italy SRL, and F. Hoffmann-La Roche Limited, outside of this work. MP reports receiving grants and personal fees from Pfizer, MSD, Menarini and Dia Sorin, outside of this work. CT has received grants in the last two years from Correvio, Biotest, Biomerieux, Gilead, Angelini, MSD, Pfizer, Thermofisher, Zambon, Shionogi, Avir Pharma and Hikma, outside of this work. All the other authors declare no conflict of interest.
